Beijing Qinghui Liannuo Biotechnology Co. Ltd. has described compounds acting as butyrophilin subfamily 3 member A1 (BTN3A1) and 2A1 ligands reported to be useful for the treatment of cancer, autoimmune, inflammatory, cardiovascular disorders and infections.
